Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nicolas Duverger is active.

Publication


Featured researches published by Nicolas Duverger.


Arteriosclerosis, Thrombosis, and Vascular Biology | 1993

Characterization of apoA-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid.

Nicolas Duverger; Nordine Ghalim; G Ailhaud; Armin Steinmetz; Jean-Charles Fruchart; Graciela Castro

Apolipoprotein (apo) A-IV has been proposed to play a role in reverse cholesterol transport. ApoA-IV-containing lipoprotein particles (A-IVLp) were isolated from human plasma and interstitial fluid and characterized by immunoaffinity chromatography. Two major A-IVLp subpopulations, lipoprotein particles containing apoA-IV with apoA-I (LpA-I:A-IV) and lipoprotein particles containing apoA-IV without apoA-I (LpA-IV), were identified. The larger subpopulation of A-IVLp is the LpA-IV that represents 70% (protein mass) of the initial particles. Only 5.8% of apoA-IV was recovered in the retained fraction after affinity chromatography with an anti-apoA-I immunosorbent. ApoA-I, apoA-II, apoA-IV, apoB, apoC-III, apoD, apoE, apoH, lecithin: cholesterol acyltransferase (LCAT), cholesteryl ester transfer (CET) protein, proline-rich protein, and a protein of Mr 59,000 were detected in the A-IVLp. These particles contain more than 20% triglycerides (lipid mass). ApoA-IV-containing particles that were isolated from plasma are heterogeneous in size, consisting of two major populations with Stokes diameters of 10.3 nm and 9.3 nm. Both subpopulations of A-IVLp contain LCAT and CET activities and promote cholesterol efflux from cholesterol-preloaded adipose cells. These data support the hypothesis that A-IVLp particles may be involved in reverse cholesterol transport.


Biochimica et Biophysica Acta | 1994

Lipoproteins containing apolipoprotein A-IV: Composition and relation to cholesterol esterification

Nicolas Duverger; Nordine Ghalim; Nathalie Theret; Jean Charles Fruchart; Graciela Castro

In order to investigate the relationship of lipid and apolipoprotein composition to cholesterol esterification in lipoproteins containing apolipoprotein (apo) A-IV, apo A-containing lipoprotein particles were isolated from fresh human plasma using a system of sequential immunoaffinity chromatography. Plasma was first depleted of apo B- and apo E-containing lipoproteins. Four major subpopulations of apo A-containing lipoprotein particles were separated: Lp A-I, Lp A-I: A-II, Lp A-IV and Lp A-I: A-IV: A-II. Lp A-IV and Lp A-I: A-IV: A-II contained less total lipid, less cholesterol and more triacylglycerol than Lp A-I and Lp A-I: A-II. Lp A-IV and Lp A-I: A-IV: A-II contained more sphingomyelin and less phosphatidylcholine than Lp A-I and Lp A-I: A-II and were richer in (16:0 + 18:0) saturated fatty acids. Among these isolated lipoprotein particles, Lp A-IV contained the highest lecithin: cholesterol acyltransferase (LCAT) activity per micrograms of protein. Cholesterol esterification rates were 2.6 +/- 0.5, 5.3 +/- 0.4 and 0.8 +/- 0.2 mumol of cholesterol per hour per mg of lipoproteins for Lp A-IV, Lp A-I and Lp A-I: A-II, respectively. The apolipoprotein and lipid composition and LCAT activity of Lp A-IV suggest that this lipoprotein may be a source of cholesterol esterification in plasma.


Biochimica et Biophysica Acta | 1993

Tangier disease : isolation and characterization of LpA-I, LpA-II, LpA-I:A-II and LpA-IV particles from plasma

Philippe Duchateau; Daniel J. Rader; Nicolas Duverger; Nathalie Theret; C. De Geitere; H.B. Brewer; Jean-Charles Fruchart; Graciela Castro

Tangier disease (TD) is characterized by extremely low plasma levels of HDL, apoA-I and apoA-II due to very rapid catabolism. However, the risk of premature coronary heart disease (CHD) is not markedly increased in TD. In order to gain insight into reverse cholesterol transport in TD, we isolated LpA-I, LpA-I:A-II, LpA-II and LpA-IV particles from fasting plasma of 5 TD patients. LpA-I composition was similar to control LpA-I, but TD LpA-I had more LCAT and CETP activity (respectively, 0.35 +/- 0.14 and 0.14 +/- 0.04 mumol of cholesterol esterified/h/micrograms of protein, and 7 +/- 2.5 and 1.4 +/- 0.3 mumol of cholesteryl ester transferred/h/micrograms of protein). In contrast, TD LpA-I:A-II had abnormal composition, with a low molar ratio of apoA-I to apoA-II (0.2-1.33). In addition, LpA-I:A-II in TD contained a substantial amount of apoA-IV compared with control, making this particle an LpA-I:A-II:A-IV complex. LpA-I:A-II from normal plasma do not promote cholesterol efflux from adipocytes cells, whereas TD LpA-I:A-II:A-IV complexes promoted cholesterol efflux from these cells. Moreover LpA-I:A-II:A-IV complexes have more LCAT and CETP activity than control (respectively 1.2 +/- 0.16 and 0.05 +/- 0.01 mumol of cholesterol esterified/h/micrograms of protein and, 41 +/- 3.7 and 1 +/- 0.4 mumol of cholesteryl ester transferred/h/micrograms of protein). The LpA-II particle in TD represented in fact an LpA-II:A-IV complex (75% mol apoA-II and 22% mol apoA-IV).(ABSTRACT TRUNCATED AT 250 WORDS)


Advances in Experimental Medicine and Biology | 1990

Lipoprotein A-I Containing Particles

Nicolas Duverger; Nordine Ghalim; Nathalie Theret; Philippe Duchateau; Gustave Aguie; Gérard Ailhaud; Graciela Castro; Jean-Charles Fruchart

Many epidemiological studies have indicated that the plasma level of high density lipoproteins (HDL) is inversely correlated with the risk for coronary artery disease1. It has been hypothesized that HDL exerts this protective effect by the “reverse” transport of excess cholesterol from peripheral tissues to the liver2.


Biochemistry | 1993

Biochemical characterization of the three major subclasses of lipoprotein A-I preparatively isolated from human plasma

Nicolas Duverger; Daniel J. Rader; Philippe Duchateau; Jean-Charles Fruchart; Graciela Castro; H B Brewer


FEBS Journal | 1991

Functional characterization of human recombinant apolipoprotein AIV produced in Escherichia coli

Nicolas Duverger; Anne Murry-Brelier; Martine Latta; Soline Reboul; Graciela Castro; Jean-François Mayaux; Jean-Charles Fruchart; John M. Taylor; Armin Steinmetz; Patrice Denefle


Archive | 2002

Method of administration of a gene of interest to a vascular tissue

Nicolas Duverger; Didier Branellec; Nathalie Aubailly; Glenda Bilder; Jeffrey Bostwick


Archive | 2002

Method of administration of a gene of interest to the heart and vasculature

Nicolas Duverger; Didier Branellec; Glenda Bilder; Jeffrey Bostwick; Nathalie Aubailly


Archive | 1996

Atherosclerosis gene therapy using monocyte line hdl production

Patrice Denefle; Nicolas Duverger


Archive | 2002

Procede d'injection d'un gene a etudier dans le coeur et le systeme vasculaire

Nicolas Duverger; Didier Branellec; Glenda Bilder; Jeffrey Bostwick; Nathalie Aubailly

Collaboration


Dive into the Nicolas Duverger's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Celine Viglietta

Institut national de la recherche agronomique

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Edward Rubin

Institut national de la recherche agronomique

View shared research outputs
Top Co-Authors

Avatar

Louis-Marie Houdebine

Institut national de la recherche agronomique

View shared research outputs
Top Co-Authors

Avatar

Steven D. Hughes

Lawrence Berkeley National Laboratory

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge